- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07314853
Utilisation de l'intelligence artificielle pour guider la thérapie liquidienne pendant la chirurgie majeure du cancer : un essai contrôlé randomisé (FOCUS-AFM)
Optimisation des Fluides en Chirurgie Cancérologique avec Gestion Assistée par IA - Essai FOCUS-AFM
The goal of this clinical trial is to learn if using artificial intelligence to guide intravenous fluid therapy during major cancer surgery can help keep blood pressure more stable compared with usual care in adult patients undergoing major cancer surgery. The main questions it aims to answer are:
- Does artificial intelligence-guided fluid therapy reduce hypotensive events during surgery?
- Does this approach improve recovery and reduce complications after major cancer surgery?
Researchers will compare artificial intelligence-guided fluid therapy with standard fluid management to see if the artificial intelligence-guided approach provides better support during surgery.
Participants will:
- Undergo major cancer surgery under general anesthesia
- Receive either artificial intelligence-guided fluid management or standard fluid management during surgery
- Be monitored during and after surgery as part of routine clinical care
- Be followed after surgery to assess recovery and possible complications
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This multicentre randomized controlled clinical trial evaluates the impact of artificial intelligence-guided intraoperative intravenous fluid therapy on hemodynamic management and postoperative outcomes in adult patients undergoing major abdominal cancer surgery.
Optimal intraoperative fluid therapy is a critical component of anesthetic management during major oncologic surgery. Both inadequate and excessive fluid administration may contribute to hemodynamic instability and postoperative complications. Episodes of intraoperative hypotension have been consistently associated with increased postoperative morbidi ty and mortality, particularly in high-risk surgical populations. Although goal-directed strategies for intraoperative fluid therapy have been proposed, their implementation in routine clinical practice remains heterogeneous and highly operator-dependent.
Advances in artificial intelligence have enabled the development of decision support systems capable of integrating continuous hemodynamic data derived from standard intraoperative monitoring. These systems are designed to assist clinicians by analyzing multiple physiologic variables in real time and providing recommendations for intravenous fluid administration aimed at supporting circulatory stability, while preserving full clinician control over treatment decisions.
In this trial, participants undergoing major abdominal cancer surgery under general anesthesia are randomly assigned to receive either artificial intelligence-guided intravenous fluid therapy or standard intravenous fluid management according to routine clinical practice. Randomization is centralized and stratified by relevant procedural factors. In the intervention group, intravenous fluid administration is supported by an artificial intelligence-based decision support system that continuously analyzes intraoperative hemodynamic data and generates recommendations for fluid challenges. Clinicians are strongly encouraged to follow the system recommendations; however, they retain full responsibility and may accept or override these recommendations based on their clinical judgment. In the control group, intraoperative fluid therapy is managed according to usual clinical practice without artificial intelligence guidance.
Standard perioperative monitoring is applied in both study groups, including continuous invasive arterial blood pressure monitoring. Intraoperative hemodynamic variables, fluid administration, and use of vasoactive medications are recorded prospectively using electronic anesthesia records and monitoring system outputs. Postoperative clinical data are collected during routine inpatient care and scheduled follow-up.
The study focuses on the intraoperative period as a key window during which hemodynamic management may influence postoperative recovery and longer-term outcomes. By evaluating an artificial intelligence-based decision support approach in a randomized multicentre setting, this trial aims to generate evidence on whether technology-assisted intravenous fluid therapy can improve intraoperative management and support better clinical outcomes in patients undergoing major cancer surgery.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: gilda pasta, MD
- Numéro de téléphone: +393498369411
- E-mail: g.pasta@istitutotumori.na.it
Sauvegarde des contacts de l'étude
- Nom: Francesca Bifulco, MD
- Numéro de téléphone: +393471752075
- E-mail: f.bifulco@istituotumori.na.it
Lieux d'étude
-
-
-
Naples, Italie, 80100
- IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale"
-
Contact:
- IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale" Cristina Romano, Data Manager
- Numéro de téléphone: +3909117770626
- E-mail: mc.romano@istitutotumori.na.it
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥ 18 years
- American Society of Anesthesiologists (ASA) Physical Status II-IV
- Undergoing major abdominal oncologic surgery (open or laparoscopic) with an expected duration >2 hours
- Planned invasive arterial pressure monitoring
- Ability to understand and sign informed consent
Exclusion Criteria:
- Significant arrhythmias (e.g., persistent atrial fibrillation)
- Severe aortic stenosis
- Emergency surgery
- Sepsis
- End-stage renal disease on dialysis
- Pregnancy
- Impossibility to cannulate the radial artery
- Refusal to participate or refusal of data processing consent
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Standard Fluid Management
Participants receive intraoperative intravenous fluid therapy managed according to usual clinical practice, without artificial intelligence guidance. Fluid administration is determined by the attending clinician based on standard monitoring and clinical judgment. |
In this intervention participants receive intraoperative intravenous fluid therapy managed according to usual clinical practice, without artificial intelligence guidance. Fluid administration is determined by the attending clinician based on standard monitoring and clinical judgment. |
|
Expérimental: AI-Assisted Fluid Management
Participants assigned to this arm receive intraoperative intravenous fluid therapy supported by an artificial intelligence-based clinical decision support system. The system analyzes real-time hemodynamic data and provides recommendations for fluid administration. Clinicians are strongly encouraged to follow these recommendations but may accept or override them based on clinical judgment. |
In this intervention, intraoperative intravenous fluid management is supported by an artificial intelligence-based clinical decision support system. The system continuously analyzes real-time hemodynamic data derived from standard intraoperative monitoring and provides recommendations for intravenous fluid administration. Clinicians are strongly encouraged to follow these recommendations but retain full responsibility and may accept or override them based on clinical judgment. The intervention is applied during the intraoperative period only and does not replace standard anesthetic care. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Intraoperative Hypotension Burden
Délai: From induction of anesthesia to the end of surgery
|
The burden of intraoperative hypotension, measured as the time-weighted average (TWA) of intraoperative hypotension, a composite measure that accounts for both the depth and duration of low arterial blood pressure over time. TWA reflects the overall hypotensive burden during surgery by integrating how low blood pressure falls and for how long it remains below predefined thresholds, assessed using continuous invasive blood pressure monitoring |
From induction of anesthesia to the end of surgery
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- FOCUS AFM
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .